Exact Sciences up 14% premarket

Shares of Exact Sciences (EXAS) are poised for an opening up move after yesterday's inadvertent posting of clinical trial results for Cologuard.

Compared to colonoscopy, the test was 92% sensitive for cancer stages I & II and 69% for precancerous polyps containing high-grade dysplasia (highest cancer risk).

FDA ad comm to vote on Cologuard March 27.

Consensus revenue estimates for 2014 and 2015 are $22.6M and $98.9M, respectively.

215 mutual funds have positions, up from 185 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs